{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DASATINIB&page=3", "query": { "condition": "DASATINIB", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 207, "total_pages": 21, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DASATINIB&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DASATINIB&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T06:31:51.603Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03516279", "title": "Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Minimal Residual Disease" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" }, { "name": "Imatinib Mesylate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nilotinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2019-06-26", "completion_date": "2031-08-31", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-07T06:31:51.603Z", "location_count": 291, "location_summary": "Fairbanks, Alaska • Goodyear, Arizona • Phoenix, Arizona + 209 more", "locations": [ { "city": "Fairbanks", "state": "Alaska" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Hot Springs", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03516279" }, { "nct_id": "NCT00101660", "title": "Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloid Leukemia", "Philadelphia-Positive Myeloid Leukemia" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 387, "start_date": "2005-02", "completion_date": "2008-04", "has_results": true, "last_update_posted_date": "2012-03-02", "last_synced_at": "2026-10-07T06:31:51.603Z", "location_count": 32, "location_summary": "Anaheim, California • Loma Linda, California • Los Angeles, California + 29 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Vallejo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00101660" }, { "nct_id": "NCT00700882", "title": "Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "dasatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2009-07-02", "completion_date": "2020-12-28", "has_results": true, "last_update_posted_date": "2023-07-03", "last_synced_at": "2026-10-07T06:31:51.603Z", "location_count": 153, "location_summary": "Little Rock, Arkansas • Stanford, California • Fort Lauderdale, Florida + 106 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Stanford", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Jupiter", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00700882" }, { "nct_id": "NCT00501410", "title": "FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "5-FU", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2007-04-23", "completion_date": "2017-03-03", "has_results": false, "last_update_posted_date": "2019-08-28", "last_synced_at": "2026-10-07T06:31:51.603Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00501410" }, { "nct_id": "NCT00744497", "title": "Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1930, "start_date": "2008-10", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2016-10-17", "last_synced_at": "2026-10-07T06:31:51.603Z", "location_count": 43, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Fayetteville, Arkansas + 35 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Corona", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00744497" }, { "nct_id": "NCT00570700", "title": "Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hormone-refractory Prostate Cancer", "Adenocarcinoma of the Prostate", "Hormone-resistant Prostate Cancer", "Prostate Cancer", "Recurrent Prostate Cancer" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 38, "start_date": "2007-07", "completion_date": "2012-02", "has_results": true, "last_update_posted_date": "2019-02-26", "last_synced_at": "2026-10-07T06:31:51.603Z", "location_count": 6, "location_summary": "Duarte, California • Loma Linda, California • Orange, California + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00570700" }, { "nct_id": "NCT04439305", "title": "Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Hematopoietic and Lymphoid Cell Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2016-02-25", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-07-20", "last_synced_at": "2026-10-07T06:31:51.603Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04439305" }, { "nct_id": "NCT00316953", "title": "Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Blastic Phase Chronic Myelogenous Leukemia", "Childhood Chronic Myelogenous Leukemia", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Meningeal Chronic Myelogenous Leukemia", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Relapsing Chronic Myelogenous Leukemia", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "dasatinib", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 48, "start_date": "2006-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-05", "last_synced_at": "2026-10-07T06:31:51.603Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00316953" }, { "nct_id": "NCT01593254", "title": "Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Phase Chronic Myeloid Leukemia" ], "interventions": [ { "name": "Imatinib", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 262, "start_date": "2012-09-12", "completion_date": "2022-04-12", "has_results": true, "last_update_posted_date": "2023-06-22", "last_synced_at": "2026-10-07T06:31:51.603Z", "location_count": 21, "location_summary": "Anaheim, California • Fontana, California • Los Angeles, California + 18 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Fontana", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "San Jose", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01593254" }, { "nct_id": "NCT00949988", "title": "A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Dasatinib and Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2009-05", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2019-08-14", "last_synced_at": "2026-10-07T06:31:51.603Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00949988" } ] }